A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)

The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV).
Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.

开始日期2023-09-09

申办/合作机构

Biotest GmbH & Co. KGaA

NCT05531149

/ Terminated临床3期

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia.

The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired pneumonia (CAP) or moderate / severe Coronavirus Disease 2019 (COVID-19) pneumonia.
Other objectives are to determine pharmacokinetic (PK) and pharmacodynamic (PD) properties of trimodulin.

开始日期2022-12-22

申办/合作机构

Biotest GmbH & Co. KGaA

NCT04576728

/ Completed临床2期

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase II Trial Investigating the Efficacy and Safety of Trimodulin (BT588) as add-on Therapy to Standard of Care in Adult Subjects With Severe COVID-19

The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
Additionally, pharmacodynamic (PD) and pharmacokinetic (PK) properties of trimodulin will be evaluated in all subjects.

开始日期2020-10-06

申办/合作机构

Biotest GmbH & Co. KGaA

100 项与 Trimodulin (Biotest) 相关的临床结果

登录后查看更多信息

100 项与 Trimodulin (Biotest) 相关的转化医学

登录后查看更多信息

100 项与 Trimodulin (Biotest) 相关的专利（医药）

登录后查看更多信息

项与 Trimodulin (Biotest) 相关的文献（医药）

2026-02-01·EUROPEAN RESPIRATORY JOURNAL

Exciting times for trimodulin

Communications

作者: Morty, Rory E

2026-02-01·EUROPEAN RESPIRATORY JOURNAL

Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models

Article

作者: Witzenrath, Martin ; Goekeri, Cengiz ; Gutbier, Birgitt ; Linke, Kerstin ; Brömel, Theresa C ; Heinz, Corina C ; Farztdinov, Vadim ; Voß, Anne ; Beule, Dieter ; Weissmüller, Sabrina ; Milek, Miha ; Taylor, Alexander ; Bischoff, Romina ; Bohlaender, Fabian ; Kershaw, Olivia ; Pennitz, Peter ; Kunder, Sandra ; Visser, Mayken ; Gruber, Achim D ; Koenig, Martin ; Mülleder, Michael ; Nouailles, Geraldine ; Ahrens, Katharina

Background:

Severe community-acquired pneumonia remains a global health challenge with high mortality despite advances in antibiotic therapy and supportive care. Immunoglobulin therapies, especially IgM-containing ones, have shown promise in enhancing host defence and reducing inflammation. The CIGMA trial highlighted the potential of trimodulin to lower mortality in patients with severe community-acquired pneumonia with high C-reactive protein and low IgM levels.

Methods:

We investigated the protective effects of trimodulin on clinical status, bacterial burden, lung integrity and inflammatory responses in murine models of lung injury, including both ventilator-induced lung injury and infection-induced models with nonsterile inflammation.

Results:

In mice, trimodulin significantly protected against lethal pneumococcal pneumonia by reducing bacterial burden and disease severity while preserving alveolar barrier integrity and limiting lung oedema. The antibacterial action of trimodulin was mediated through opsonophagocytosis, and its anti-inflammatory effects operated independently of the latter. When combined with ampicillin, trimodulin exhibited enhanced suppression of inflammation.

Conclusion:

Our findings in preclinical pneumonia models suggest that trimodulin could be a promising therapy for severe community-acquired pneumonia. We provide evidence that trimodulin enhances host defence, reduces detrimental pulmonary inflammation and barrier dysfunction, and limits pulmonary oedema, which may explain the beneficial effects observed in patients with severe community-acquired pneumonia.

2023-09-01·Drugs in R&D

Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo®] Obtained from a Manufacturing Process Preserving IgA/IgM Potential of Human Plasma

Article

作者: Hannappel, Achim ; Duellberg, Christian ; Maneg, Oliver ; Kistner, Steffen

BACKGROUND AND OBJECTIVE:

Human plasma is used for the generation of several life-saving drugs and contains valuable antibodies from the immunoglobulin classes IgG, IgM and IgA. Purified intravenous IgG solutions (IVIGs) form the majority of plasma-derived medicine to treat patients with various forms of immunodeficiencies. In conventional IVIG manufacturing processes, immunoglobulin classes IgM and IgA are often discarded as contaminants, but these antibody classes have been proven to be effective for the treatment of acute bacterial infections. Considering the increase in demand for human plasma-derived products and the ethical value of the raw material, a more resource-saving usage of human plasma is needed. Intensive research over the last decades showed that adverse reactions to IVIGs depend on the presence of thrombogenic factors, partially unfolded proteins, non-specific activation of the complement system, and blood group specific antibodies. Therefore, new IVIG preparations with reduced risks of adverse reactions are desirable.

METHOD:

A new manufacturing process that yields two biologics was established and quality attributes of the new IVIG solution (Yimmugo^®) obtained from this process are presented.

RESULTS:

Here, we provide a biochemical characterization of Yimmugo^®, a new 10% IVIG preparation. It is derived from human blood plasma by a combined manufacturing process, where IgM and IgA are retained for the production of a new biologic (trimodulin, currently under investigation in phase III clinical trials). Several improvements have been implemented in the manufacturing of Yimmugo^® to reduce the risk of adverse reactions. Gentle and efficient mixing by vibration (called "vibromixing") during a process step where proteins are at risk to aggregate was implemented to potentially minimize protein damage. In addition, a dedicated process step for the removal of the complement system activator properdin was implemented, which resulted in very low anticomplementary activity levels. The absence of measurable thrombogenic activity in combination with a very high degree of functional monomeric antibodies predict excellent efficacy and tolerability.

CONCLUSION:

Yimmugo^® constitutes a new high quality IVIG preparation derived from a novel manufacturing process that takes advantage of the full therapeutic immunoglobulin potential of human plasma.

项与 Trimodulin (Biotest) 相关的新闻（医药）

2026-06-08

·动脉网

在先进疗法和疾病负担加重的推动下，肺炎市场预计在预测期（2026-2036年）实现强劲增长 DelveInsightPneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden

The growth of the pneumonia market is expected to be primarily driven by an expanding patient population and advancements in diagnostic methods. Additionally, the expected launch of emerging therapies such as Tosatoxumab (AR-301) (Aridis Pharmaceuticals), AON-D21 (Aptarion Biotech), Trimodulin (BT588) (Biotest AG), VAX-24 and VAX-31 (Vaxcyte, Inc.), PCV24 (CanSinoBIO), IVT PCV-25 (Inventprise), and others will further propel the market forward.. 肺炎市场的增长预计将主要由患者群体的扩大和诊断方法的进步所驱动。此外，Tosatoxumab（AR-301）（Aridis Pharmaceuticals）、AON-D21（Aptarion Biotech）、Trimodulin（BT588）（Biotest AG）、VAX-24 和 VAX-31（Vaxcyte, Inc.）、PCV24（康希诺生物）、IVT PCV-25（Inventprise）等新兴疗法的预期上市将进一步推动市场发展。LAS VEGAS 拉斯维加斯, ，June 8, 2026 2026年6月8日/PRNewswire/ -- Recently published Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /美通社/ -- 最近发布的《肺炎市场洞察》报告全面解析了当前的治疗实践、肺炎新兴药物、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Pneumonia Market Summary 肺炎市场概要The total pneumonia treatment market size is expected to grow positively by 2036 in the leading markets. 到2036年，主要市场的肺炎治疗总市场规模预计将实现正增长。The United States accounted for the largest pneumonia treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 与欧盟四国（德国、法国、意大利和西班牙）、英国和日本等其他主要市场相比，美国在2025年占据了最大的肺炎治疗市场规模。In the United States, the annual incidence of community-acquired pneumonia (CAP) is estimated at approximately 在美国，社区获得性肺炎（CAP）的年发病率估计约为24.8 cases per 10,000 每万人24.8例adults, with rates increasing significantly with advancing age. 成年人，且患病率随年龄增长而显著上升。Leading pneumonia companies, such as 领先的肺炎相关企业，例如Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, Aridis Pharmaceuticals，Aptarion Biotech，Biotest AG，Vaxcyte, Inc.，康希诺生物，Inventprise，BioVersys，and others, are developing new pneumonia treatment drugs that can be available in the pneumonia market in the coming years. 以及其他公司，正在开发新的肺炎治疗药物，这些药物有望在未来几年内上市。The promising pneumonia therapies in clinical trials include 临床试验中颇具前景的肺炎疗法包括Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, BV100, 托萨特珠单抗（AR-301）、AON-D21、曲莫杜林（BT588）、VAX-24、VAX-31、PCV24、IVT PCV-25、BV100，and others. 以及其他。Discover what is the global pneumonia therapeutics market size @ 了解全球肺炎治疗药物市场规模 @https://www.delveinsight.com/report-store/pneumonia-pneumococcal-market https://www.delveinsight.com/report-store/pneumonia-pneumococcal-marketKey Factors Driving the Growth of the Pneumonia Market 推动肺炎市场增长的关键因素Rising Pneumonia Incident Cases: 肺炎病例数上升：As per the analysis, the total incident cases of pneumonia are expected to increase during the forecast period (2026–2036). This anticipated rise is primarily driven by demographic shifts, particularly the aging population, as older adults are at significantly higher risk of developing pneumonia due to declining immune function and a greater prevalence of chronic comorbid conditions.. 根据分析，预计在预测期（2026–2036年）内，肺炎的总发病病例数将增加。这一预期增长主要由人口结构变化驱动，尤其是人口老龄化，因为老年人由于免疫功能下降以及慢性共病患病率较高，罹患肺炎的风险显著增加。Growing Geriatric Population: 老年人口不断增长：The expanding aging population significantly contributes to the growth of the pneumonia market. Older adults are more susceptible to respiratory infections due to weakened immune systems and age-related comorbidities. 不断扩大的老龄化人口显著推动了肺炎市场的增长。由于免疫系统减弱以及与年龄相关的合并症，老年人更容易受到呼吸道感染的影响。Increasing Burden of Chronic Diseases: 慢性疾病的负担日益加重：Chronic health conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, and cardiovascular diseases increase susceptibility to pneumonia. The rising prevalence of these conditions worldwide is leading to a higher incidence of pneumonia-related complications, thereby expanding the demand for effective treatment options and supportive therapies.. 慢性阻塞性肺疾病（COPD）、哮喘、糖尿病和心血管疾病等慢性健康状况会增加患肺炎的易感性。这些状况在全球范围内的患病率不断上升，导致肺炎相关并发症的发生率增高，从而扩大了对有效治疗方案和支持性疗法的需求。Advancements in Diagnostics and Treatment Technologies: 诊断与治疗技术的进步：Technological innovations in molecular diagnostics, PCR-based testing, and rapid point-of-care diagnostics are enabling earlier and more accurate detection of pneumonia pathogens. These advances improve treatment outcomes and support the development of targeted therapies, contributing significantly to market growth.. 分子诊断、基于PCR的检测以及快速即时检测领域的技术创新，使得对肺炎病原体的检测更加早期和准确。这些进步改善了治疗结果，并支持靶向疗法的发展，从而显著推动了市场增长。Increasing Adoption of Vaccination Programs: 疫苗接种计划的日益普及：Government initiatives and global immunization campaigns promoting pneumococcal and influenza vaccination are boosting demand for pneumonia prevention solutions. 政府倡议和全球免疫运动正在推动肺炎球菌和流感疫苗接种，从而提升了对肺炎预防解决方案的需求。Launch of Emerging Pneumonia Drugs: 新兴肺炎药物的上市：The dynamics of the pneumonia market are expected to change in the coming years due to the launch of emerging therapies such as 由于新兴疗法（如）的推出，预计肺炎市场动态将在未来几年发生变化Tosatoxumab (AR-301) 托沙妥昔单抗（AR-301）(Aridis Pharmaceuticals), （Aridis Pharmaceuticals）AON-D21 AON-D21(Aptarion Biotech), （Aptarion Biotech），Trimodulin (BT588) Trimodulin (BT588)(Biotest AG), （Biotest AG），VAX-24 and VAX-31 VAX-24 和 VAX-31(Vaxcyte, Inc.), （Vaxcyte 公司）PCV24 PCV24(CanSinoBIO), （康希诺生物）IVT PCV-25 IVT PCV-25(Inventprise), (Inventprise)BV100 BV100(BioVersys), and others. (BioVersys) 等。According to Ramandeep Singh, Senior Consultant of Forecasting and Analytics at DelveInsight, the pneumonia market in the 7MM is expected to witness steady growth during the forecast period (2026–2036), driven by the rising incidence of community- and hospital-acquired pneumonia, increasing antimicrobial resistance, improved diagnostic capabilities, and the introduction of novel targeted therapies and vaccines.. 根据DelveInsight预测与分析高级顾问Ramandeep Singh的观点，在预测期（2026–2036年）内，七大主要市场（7MM）的肺炎市场预计将实现稳步增长，这一增长得益于社区获得性肺炎和医院获得性肺炎发病率的上升、抗菌药物耐药性的增加、诊断能力的提升，以及新型靶向疗法和疫苗的推出。Pneumonia Market Analysis 肺炎市场分析The treatment of pneumonia is determined by its underlying cause, the severity of the infection, and individual patient characteristics. 肺炎的治疗取决于其根本病因、感染的严重程度以及患者的个体特征。Bacterial pneumonia is generally managed with suitable antibiotic therapy, whereas viral pneumonia is often treated with supportive care and, in certain situations, antiviral agents. 细菌性肺炎通常采用合适的抗生素治疗，而病毒性肺炎则常采取支持性护理，并在特定情况下使用抗病毒药物。Supportive measures typically include adequate rest, proper hydration, and hospitalization in severe cases. 支持性措施通常包括充分休息、适当补水，以及在重症情况下住院治疗。Preventive strategies, particularly vaccination against pathogens like Streptococcus pneumoniae and influenza viruses, are also essential in reducing the risk of specific forms of pneumonia. 预防策略，特别是针对肺炎链球菌和流感病毒等病原体的疫苗接种，对于降低特定类型肺炎的风险也至关重要。Several therapies approved by the U.S. Food and Drug Administration are available for pneumonia treatment, including 美国食品药品监督管理局批准的多种肺炎治疗疗法可供选择，包括XACDURO (sulbactam + durlobactam) XACDURO（舒巴坦 + 杜洛巴坦）and 和ZEVTERA (ceftobiprole medocaril) ZEVTERA（头孢比普罗酯）, among others. ，以及其他。In addition, emerging pipeline candidates such as 此外，新兴的管线候选药物如Tosatoxumab (AR-301) 托萨妥昔单抗（AR-301）(Aridis Pharmaceuticals), （Aridis Pharmaceuticals）AON-D21 AON-D21(Aptarion Biotech), （Aptarion Biotech）Trimodulin (BT588) 特里莫杜林（BT588）(Biotest AG), （Biotest AG）VAX-24 and VAX-31 VAX-24 和 VAX-31(Vaxcyte, Inc.), （Vaxcyte, Inc.）PCV24 PCV24(CanSinoBIO), （康希诺生物）IVT PCV-25 IVT PCV-25(Inventprise), (Inventprise),BV100 BV100(BioVersys), and others are progressing through development and are expected to further reshape the pneumonia treatment landscape through innovative targeted mechanisms. （BioVersys）等公司正在推进研发进程，预计将通过创新的靶向机制进一步重塑肺炎治疗格局。Pneumonia Competitive Landscape 肺炎竞争格局Some of the pneumonia drugs under development include 正在开发的一些肺炎药物包括Tosatoxumab (AR-301) 托沙妥昔单抗（AR-301）(Aridis Pharmaceuticals), （Aridis Pharmaceuticals）AON-D21 AON-D21(Aptarion Biotech), （Aptarion Biotech）Trimodulin (BT588) Trimodulin (BT588)(Biotest AG), （Biotest AG）VAX-24 and VAX-31 VAX-24 和 VAX-31(Vaxcyte, Inc.), （Vaxcyte, Inc.）PCV24 PCV24(CanSinoBIO), （康希诺生物）IVT PCV-25 IVT PCV-25(Inventprise), （Inventprise）BV100 BV100(BioVersys), and others. （BioVersys）以及其他公司。Aridis Pharmaceuticals' AR-301 (tosatoxumab) Aridis Pharmaceuticals 公司的 AR-301（托沙妥珠单抗）is a fully human IgG1 monoclonal antibody developed to specifically bind and neutralize the alpha-toxin produced by 是一种全人源IgG1单克隆抗体，旨在特异性结合并中和由Staphylococcus aureus 金黄色葡萄球菌, a major virulence factor present in both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains. By inhibiting this toxin, AR-301 helps limit toxin-induced damage to host tissues while maintaining immune cell functionality. Since its mechanism of action does not depend on the bacterium's antibiotic resistance status, it can potentially be effective against infections caused by both MRSA and MSSA strains.. ，这是一种存在于耐甲氧西林金黄色葡萄球菌（MRSA）和甲氧西林敏感金黄色葡萄球菌（MSSA）菌株中的主要毒力因子。通过抑制这种毒素，AR-301 有助于限制毒素对宿主组织造成的损伤，同时保持免疫细胞的功能。由于其作用机制不依赖于细菌的抗生素耐药状态，因此它有可能对由 MRSA 和 MSSA 菌株引起的感染均有效。In July 2023, the US FDA granted Qualified Infectious Disease Product (QIDP) designation to tosatoxumab (AR-301), supporting its accelerated clinical development as an adjunctive treatment for 2023年7月，美国食品药品监督管理局（FDA）授予托沙妥昔单抗（AR-301）“合格传染病产品”（QIDP）资格，以支持其作为辅助治疗药物的加速临床开发Staphylococcus aureus 金黄色葡萄球菌pneumonia. 肺炎Top-line results from the first of two planned global Phase III studies assessing a single dose of AR-301 alongside standard-of-care antibiotics for ventilator-associated pneumonia (VAP) caused by 评估单剂量AR-301联合标准护理抗生素治疗由以下原因引起的呼吸机相关性肺炎（VAP）的两项计划全球III期研究中第一项研究的初步结果Staphylococcus aureus 金黄色葡萄球菌were announced in September 2023. The therapy demonstrated a favorable safety profile in the full analysis set (FAS). In the microbiologically confirmed subgroup, an 11.3% numerical increase in clinical cure rate at Day 21 was observed; however, this improvement did not achieve statistical significance.. 于2023年9月公布。该疗法在全分析集（FAS）中显示出良好的安全性特征。在微生物学确认的亚组中，第21天的临床治愈率数值上提高了11.3%；然而，这一改善未达到统计学显著性。Aptarion Biotech's AON-D21 Aptarion Biotech 公司的 AON-D21is an investigational L-aptamer, a synthetic nucleic acid–based therapeutic, designed to selectively block complement factor C5a, an important inflammatory mediator involved in excessive immune activation. Overactivation of C5a can drive severe inflammation, multi-organ dysfunction, and increased mortality. 是一种在研的L-适配体，一种基于合成核酸的治疗药物，旨在选择性阻断补体因子C5a，这是一种参与过度免疫激活的重要炎症介质。C5a的过度激活可导致严重炎症、多器官功能障碍以及死亡率升高。Preclinical studies have shown that AON-D21 is effective in translational models of pneumonia and sepsis, and it has also demonstrated potential in lung cancer, particularly when combined with immune checkpoint inhibitors, suggesting that modulation of C5a may have broad therapeutic applications across immune-driven diseases.. 临床前研究表明，AON-D21在肺炎和脓毒症的转化模型中有效，并且在肺癌中也显示出潜力，尤其是在与免疫检查点抑制剂联合使用时，这表明调节C5a可能在免疫驱动的疾病中具有广泛的治疗应用。The anticipated launch of these emerging therapies are poised to transform the pneumonia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the pneumonia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年重塑肺炎市场格局。随着这些前沿疗法不断成熟并获得监管批准，预计将改变肺炎市场的现状，提供新的护理标准，并为医疗创新和经济增长带来新机遇。Discover more about new antibiotics for pneumonia in development @ 了解更多关于正在研发中的新型肺炎抗生素信息 @Pneumonia Drugs 肺炎药物Recent Developments in the Pneumonia Market 肺炎市场的最新发展In 在March 2026, BioVersys 2026年3月，BioVersysannounced that the FDA had given the go-ahead for enrolling patients in the United States for the global Phase 3 RIV-TARGET clinical trial (NCT07326540). 宣布美国食品药品监督管理局（FDA）已批准在全球III期RIV-TARGET临床试验（NCT07326540）中纳入美国患者。In 在January 2026, 2026年1月，AON-D21 completed patient enrollment in the international Phase II ADCAP trial assessing its efficacy and safety in patients with severe community-acquired pneumonia. AON-D21已完成国际II期ADCAP试验的患者入组，该试验旨在评估其在重症社区获得性肺炎患者中的有效性和安全性。In 在March 2025, 2025年3月，AON-D21 received clearance of its US Investigational New Drug (IND) application, along with approval to expand the ongoing Phase II ADCAP trial to enroll up to 150 patients. AON-D21 的美国新药临床试验申请（IND）已获得批准，同时获准将正在进行的 ADCAP II 期临床试验的入组患者人数扩大至最多 150 名。What is Pneumonia? 什么是肺炎？Pneumonia is a respiratory infection that affects the lungs, specifically the tiny air sacs known as alveoli. In people with pneumonia, these air sacs become inflamed and may fill with fluid or pus, making it difficult for oxygen to pass into the bloodstream. This condition can be caused by bacteria, viruses, or fungi and may range from mild to severe, particularly in young children, older adults, and individuals with weakened immune systems. 肺炎是一种影响肺部的呼吸道感染，尤其累及被称为肺泡的微小气囊。在肺炎患者中，这些肺泡会发生炎症，并可能充满液体或脓液，从而阻碍氧气进入血液。该病可由细菌、病毒或真菌引起，病情轻重不一，在幼儿、老年人以及免疫系统较弱的人群中尤为严重。Common symptoms include cough, fever, chills, chest pain, shortness of breath, and fatigue. Pneumonia can be acquired in the community, hospitals, or healthcare settings, and timely diagnosis and treatment, such as antibiotics for bacterial infections or supportive care, are important to prevent complications and improve recovery.. 常见症状包括咳嗽、发热、寒战、胸痛、呼吸急促和疲劳。肺炎可能在社区、医院或医疗机构中感染，及时诊断和治疗（如针对细菌感染的抗生素治疗或支持性护理）对于预防并发症和促进康复至关重要。Pneumonia Epidemiology Segmentation 肺炎流行病学细分The pneumonia epidemiology section provides insights into the historical and current pneumonia patient pool and forecasted trends for the leading markets. Hospital-acquired pneumonia is associated with a significant risk of mortality, with ventilator-associated pneumonia reporting all-cause mortality rates of . 肺炎流行病学部分提供了对主要市场历史及当前肺炎患者群体和预测趋势的见解。医院获得性肺炎与显著的死亡风险相关，其中呼吸机相关性肺炎的全因死亡率报告为。20–50% 20–50%. 。The pneumonia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 肺炎治疗市场报告提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下：Total Incident Cases of Pneumonia 肺炎总病例数Clinical Subtype-specific Incident Cases of Pneumonia 肺炎的临床亚型特异性新发病例Etiology-specific Incident Cases of Pneumonia 按病因分类的肺炎新发病例Treated Cases of Pneumonia 肺炎治疗病例Pneumonia Market Report Metrics 肺炎市场报告指标Details 详情Study Period 学习周期2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 7国集团[美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Pneumonia Epidemiology Segmentation 肺炎流行病学细分Total Incident Cases of Pneumonia, Clinical Subtype-specific Incident Cases of Pneumonia, Etiology-specific Incident Cases of Pneumonia, and Treated Cases of Pneumonia 肺炎总发病病例数、临床亚型特异性肺炎发病病例数、病因特异性肺炎发病病例数以及肺炎治疗病例数Key Pneumonia Companies 主要肺炎企业Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, Basilea Pharmaceutica, Innoviva Specialty Therapeutics, and others Aridis Pharmaceuticals、Aptarion Biotech、Biotest AG、Vaxcyte, Inc.、康希诺生物、Inventprise、BioVersys、Basilea Pharmaceutica、Innoviva Specialty Therapeutics 等Key Pneumonia Therapies 关键肺炎疗法Tosatoxumab (AR-301), AON-D21, Trimodulin (BT588), VAX-24, VAX-31, PCV24, IVT PCV-25, BV100, ZEVTERA, XACDURO, and others 托萨妥珠单抗（AR-301）、AON-D21、曲莫杜林（BT588）、VAX-24、VAX-31、PCV24、IVT PCV-25、BV100、ZEVTERA、XACDURO 等Scope of the 的范围Pneumonia 肺炎Market Report 市场报告Therapeutic Assessment: 治疗性评估：Pneumonia current marketed and emerging therapies 肺炎的现有上市疗法及新兴疗法Pneumonia 肺炎Market Dynamics: 市场动态：Key Market Forecast Assumptions of Emerging Pneumonia Drugs and Market Outlook 新兴肺炎药物的关键市场预测假设及市场前景Competitive Intelligence Analysis: 竞争情报分析：SWOT analysis and Market entry strategies SWOT分析与市场进入策略Unmet Needs, KOL's views, Analyst's views, Pneumonia Market Access and Reimbursement 未满足的需求、关键意见领袖的观点、分析师的观点、肺炎市场准入与报销Download the report to understand which region dominates pneumonia therapeutics market @ 下载报告以了解哪个地区在肺炎治疗市场占据主导地位 @Pneumonia Market Analysis 肺炎市场分析Table of Contents 目录1 1Pneumonia Market Key Insights 肺炎市场关键洞察2 2Pneumonia Market Report Introduction 肺炎市场报告简介3 3Pneumonia Market Overview at a Glance 肺炎市场概览3.1 3.1Market Share (%) Distribution of Pneumonia by Therapies in the 7MM in 2025 2025年七大主要市场（7MM）按治疗方案划分的肺炎市场份额（%）分布3.2 3.2Market Share (%) Distribution of Pneumonia by Therapies in the 7MM in 2036 2036年七国市场（7MM）肺炎治疗药物市场份额（%）分布4 4Methodology 方法论5 5Executive Summary 执行摘要6 6Key Events 关键事件7 7Disease Background and Overview: Pneumonia 疾病背景与概述：肺炎7.1 7.1Introduction 简介7.2 7.2Classification 分类7.3 7.3Causes 原因7.4 7.4Signs and Symptoms 体征与症状7.5 7.5Pathophysiology 病理生理学7.6 7.6Clinical features 临床特征7.7 7.7Diagnosis 诊断7.8 7.8Treatment and Management 治疗与管理8 8Epidemiology and Patient Population of Pneumonia in the 7MM 七大主要市场肺炎的流行病学与患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale 假设与理由8.3 8.3Total Incident Cases of Pneumonia in the 7MM 七国市场（7MM）肺炎总发病病例数8.4 8.4The US 美国8.4.1 8.4.1Total Incident Cases of Pneumonia 肺炎总发病病例数8.4.2 8.4.2Clinical subtype-specific Incident Cases of Pneumonia 肺炎的临床亚型特异性新发病例8.4.3 8.4.3Etiology-specific Incident Cases of Pneumonia 按病因分类的肺炎新发病例8.4.4 8.4.4Treated Cases of Pneumonia 肺炎治疗病例8.5 8.5EU4 and the UK 欧盟四国与英国8.6 8.6Japan 日本9 9Pneumonia Patient Journey 肺炎患者就诊历程10 十Marketed Pneumonia Therapies 已上市的肺炎治疗药物10.1 10.1Key Cross Competition 关键交叉竞争10.2 10.2ZEVTERA (ceftobiprole medocaril sodium): Basilea Pharmaceutica/ Innoviva Specialty Therapeutics ZEVTERA（头孢比普罗酯甲氧基钠）：Basilea Pharmaceutica/Innoviva Specialty Therapeutics10.2.1 10.2.1Product Description 产品描述10.2.2 10.2.2Regulatory Milestone 监管里程碑10.2.3 10.2.3Other Developmental Activities 其他发展性活动10.2.4 10.2.4Clinical Trials Information 临床试验信息10.2.5 10.2.5Safety and Efficacy 安全性和有效性10.2.6 10.2.6Analyst Views 分析师观点10.3 10.3XACDURO (sulbactam + durlobactam): Innoviva Specialty Therapeutics XACDURO（舒巴坦 + 杜洛巴坦）：Innoviva Specialty TherapeuticsList to be continued in the final report. 清单将在最终报告中继续列出。11 十一Emerging Pneumonia Therapies 新兴肺炎疗法11.1 11.1Key Cross Competition 关键交叉竞赛11.2 11.2Tosatoxumab (AR-301): Aridis Pharmaceuticals 托萨妥昔单抗（AR-301）：Aridis Pharmaceuticals11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Other Developmental Activities 其他发展活动11.2.3 11.2.3Clinical Trials Information 临床试验信息11.2.4 11.2.4Safety and Efficacy 安全性与有效性11.2.5 11.2.5Analyst Views 分析师观点11.3 11.3AON-D21: Aptarion Biotech AON-D21：阿普塔里昂生物技术公司List to be continued in the final report. 清单将在最终报告中继续列出。12 12Pneumonia: Market Analysis 肺炎：市场分析12.1 12.1Key Findings 主要发现12.2 12.2Key Pneumonia Market Forecast Assumptions 关键肺炎市场预测假设12.3 12.3Pneumonia Market Outlook 肺炎市场前景12.4 12.4Conjoint Analysis 联合分析12.5 12.5Total Market Size of Pneumonia in the 7MM 七国市场（7MM）肺炎总市场规模12.6 12.6Market Size of Pneumonia by Therapies in the 7MM 七大主要市场中按疗法划分的肺炎市场规模12.7 12.7The US Pneumonia Market 美国肺炎市场12.8.1 12.8.1Total Market Size of Pneumonia 肺炎市场总规模12.8 12.8EU4 and the UK Pneumonia Market 欧盟四国与英国肺炎市场12.9 12.9Japan Pneumonia Market 日本肺炎市场13 13Key Opinion Leaders' Views on Pneumonia 关键意见领袖对肺炎的看法14 十四Pneumonia Market SWOT Analysis 肺炎市场SWOT分析15 15Pneumonia Market Unmet Needs 肺炎市场未满足的需求16 十六Pneumonia Market Access and Reimbursement 肺炎市场准入与报销16.1 16.1The US 美国16.2 16.2In EU4 and the UK 在欧盟和英国16.3 16.3Japan 日本17 17Acronyms and Abbreviations 缩略语和缩写18 十八Bibliography 参考文献19 十九Pneumonia Market Report Methodology 肺炎市场报告方法论Related Reports 相关报告Pneumonia, Pneumococcal Clinical Trial Analysis 肺炎链球菌性肺炎临床试验分析Pneumonia, Pneumococcal Pipeline Insight 肺炎链球菌性肺炎研发管线洞察– –2026 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pneumonia, pneumococcal companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键肺炎和肺炎球菌公司的全面见解，包括Biotest AG, Vaxcyte, Inc., Eubiologics Ltd., Eagle Pharmaceuticals, GlaxoSmithKline Biotest AG、Vaxcyte, Inc.、Eubiologics Ltd.、Eagle Pharmaceuticals、葛兰素史克, ，among others. 其中包括。Community-acquired Bacterial Pneumonia Market 社区获得性细菌性肺炎市场Community-acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2034 社区获得性细菌性肺炎市场洞察、流行病学及市场预测（至2034年）report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CABP companies including 报告提供对疾病的深入理解、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键CABP公司，包括Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix,. 纳布里瓦治疗公司、美林塔治疗公司、若杉制药、森林制药、辉瑞、帕拉特克制药、坎伯兰制药公司、泰万斯生物制药、默沙东公司、库比斯特制药有限责任公司、盐野义公司、艾尔建、伊戈尔制药公司、Combioxin SA、武田制药、TiGenix。and others. 等等。Hospital-acquired and Ventilator-associated Bacterial Pneumonia 医院获得性肺炎和呼吸机相关性细菌性肺炎Market 市场Hospital-acquired and Ventilator-associated Bacterial Pneumonia 医院获得性及呼吸机相关性细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HABP/VABP companies including 本报告深入解析了疾病状况、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的HABP/VABP企业，包括Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio 巴塞尔制药、默克、盐野义、辉瑞、Aridis Pharmaceuticals、Polyphor、Aerucin、Motif Bio, ，and others. 以及其他。Bacterial Pneumonia 细菌性肺炎Market 市场Bacterial Pneumonia 细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumonia companies including 本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和主要的细菌性肺炎企业，包括Pfizer, Forecast Laboratories, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Melinta Therapeutics Inc., Evopoint Biosciences Inc., Paratek Pharmaceuticals Inc., Wockhardt, Clarametyx Biosciences Inc., AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc., Bayer 辉瑞公司、Forecast Laboratories、Melinta Therapeutics Inc.、默沙东有限责任公司、Melinta Therapeutics Inc.、Evopoint Biosciences Inc.、Paratek Pharmaceuticals Inc.、Wockhardt、Clarametyx Biosciences Inc.、阿斯利康、Cumberland Pharmaceuticals、Eagle Pharmaceuticals Inc.、拜耳, ，and others. 等等。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升业绩。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [email protected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comLogo: 标志：https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpgSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 请求演示

2025-04-15

·PRNewswire

Westbourne River Partners letter to Biotest AG

LONDON, April 15, 2025 /PRNewswire/ -- Westbourne River Partners letter to Biotest AG with respect to the delisting offer made by Grifols S.A. to shareholders of Biotest: Biotest AG Attn. Peter Jannsen Landsteinerstr. 5 D-63303 Dreieich Cc: Supervisory Board Dear Peter, We are writing to you on behalf of Westbourne River Event Master Fund ("Westbourne River" or "we"), the largest minority shareholder in Biotest AG ("Biotest" or the "Company"), with respect to the delisting offer made by Grifols S.A. ("Grifols") to shareholders of the Company. We are deeply concerned about the decision of the management board to support the delisting, and we ask that the management and supervisory boards consider the appropriateness of (A) the decision to delist and (B) the price at which the delisting offer has been made. At their investor event in February 2025, Grifols clearly stated that it would like to integrate Biotest into their larger operations. The simplest means for Grifols to accomplish this, given their 97% voting control of the Company, would be to launch a domination agreement. Indeed, the only structural measures available under German law for Grifols to achieve "integration" are (1) a squeeze-out (which would require Grifols to obtain a minimum of 90% of the Company's total capital) or, more realistically, (2) a domination agreement. Without undertaking one of these measures, Biotest will continue to be required to operate on an arm's length basis with Grifols. Instead, Grifols are pursuing a delisting. On its face, and as described in further detail below, this strikes us as an attempt to scare minority shareholders into tendering their shares at below fair value, and to significantly hamper minority shareholders from monitoring the Company's progress and business plan ahead of an eventual undertaking of one of the structural measures outlined above. Delisting will not achieve Grifols's goal of integration. Delisting will, however, reduce the disclosure obligations of the Company and the transparency into the Company's business that minority shareholders currently have. Given the lack of liquidity in Biotest ordinary and preference shares, Grifols would be required to instruct an IDW-S1 valuation that would value the Company based on its own business plan for either a squeeze-out or a domination agreement. We firmly believe that valuation would be significantly above the stock market price. The lack of transparency that would come with delisting ahead of undertaking one of these measures would leave minority shareholders largely in the dark with respect to the business plan and resulting valuation. As such, delisting carries the very real threat of being harmful to minority shareholders. In early February 2025, Grifols – represented by its board member, Tomas Daga – reached out to us and offered to buy our stake in Biotest. When we suggested that they should use the structural measures available to them under German law, Mr. Daga dismissed this option, stating that Grifols didn't want to go through a valuation exercise and guarantee dividends. Instead, he asserted that they were going to delist the Company, and that our options were therefore either to sell our stake now or to remain in a private vehicle following the delisting. As you are aware, we immediately relayed this conversation, our concerns and a request to oppose a delisting offer to the Chairman of the supervisory board via phone and email, who assured us in response that Biotest "(took) the matter very seriously". Now, less than two months later, the fact that the management board, which you chair, has already entered into a delisting agreement with Grifols is extremely disappointing and suggests that the Chairman of the supervisory board's reassurance in February was an empty one. This reinforces our long-held concern that the Company is acting in the interest of its majority shareholder rather than in the interest of all shareholders. Two recent examples further highlight the basis for these concerns: First, in November 2024, Biotest's cash flow guidance implied a €50-80 million cash burn in Q4 2024. However, the actual FY 2024 results, published in February 2025, indicated a cash inflow of roughly €40 million in that period. In other words, approximately €100 million of outperformance versus Company guidance given just seven weeks prior to the end of the year. In the interim period, Mr. Daga made us the offer described above at €30 per preference share. He justified the low bid by significantly disparaging the Company and its management and referring to the expected significant cash burn. Had the Company's original guidance been similar to its actual ultimate performance, this argument about cash burn would have been obviously spurious. Second, on 31 March 2025 – the same day as the announcement of the delisting offer – the Company released guidance indicating an operating loss in 2025 of over €55 million. This guidance stands in stark contrast to the Company's operating profit in 2024 of €95 million. Despite our questions during the full-year earnings call and requests for a detailed explanation, we have received no satisfactory answers explaining an expected €150 million decrease in year-over-year operating profits. Without any other reasonable explanations, we are left to fear that the Company's management board is making unjustifiably conservative projections that may have a manipulative effect on the stock price and, if and when Grifols launch a squeeze-out or domination agreement process, would materially reduce the IDW-S1 valuation process and serve Grifols to the detriment of other shareholders. This is particularly relevant now as Biotest is about to launch Fibrinogen and is progressing with the phase-III trial of Trimodulin. In Grifols' own words, these products are expected to have a market opportunity of over $800 million and over $2 billion, respectively. According to Grifols' analysts' comments published following the delisting offer, Grifols is making the offer now to buy out minority shareholders at a cheap price ahead of progression of these products, which is expected to substantially increase Biotest's valuation. Without the fulsome disclosure requirements of a listed company, minority shareholders would be far less able to track and compare the Company's projections and results versus prior results and public commentary (both by itself and by Grifols regarding Biotest's business) and would therefore be unable to call attention to practices that appear to unfairly harm minority shareholders. In other words, if, in the future, the Company were to produce artificially conservative business plans under a new reduced disclosure requirement, it would be more difficult to discover and hold the Company to account. For these reasons, we ask that the Company reconsider the appropriateness of delisting, especially if the prices of the delisting offer remain unchanged. As indicated, we also view the terms of the offer as being made at a price materially less than fair value. When Grifols made a takeover offer for the Company in 2021, they agreed to pay €43 per ordinary share and €37 per preference share. Given that the economic rights of the preference shares and the ordinary shares are the same, we believed at the time (and still believe) that the value of these shares should be the same. Indeed, an IDW-S1 valuation would likely value the preference shares and ordinary shares at the same level. Even if one assumes that the ordinary shares carry a higher value than the preference shares (which, as described above, would likely not be the case in an IDW-S1 valuation), it is clear from Grifols's own statements that they believe (like we do) that Biotest has made significant progress in the intervening years. Presumably, then, further value will have accrued to the Company, and the current value of the company should be at a significant premium to the price Grifols paid in 2021, for both share classes. Instead, we find Grifols offering the same price per ordinary share as they offered in 2021, and 19% less per preference share. We don't believe that there is any fundamentals-based rationale for such a valuation. Ostensibly, Grifols is launching the offer for preference shares at the statutory minimum price. Grifols' shareholding has increased since the end of 2024. We were approached with an offer to buy our stake at €30 per preference share. We understand that other large minority shareholders were approached with the same offer, and that Grifols were in fact able to acquire additional shares this year at €30 per preference share. This likely defines the statutory minimum they would need to pay for a delisting offer. Several boards supporting delisting offers in the last few years have argued in favor of these offers on the basis that they provide exit liquidity for shareholders. Here, this argument doesn't apply: we understand that Grifols has contacted other shareholders in the way they have contacted us. If that is the case, shareholders will have already had the opportunity to sell at €30 per preference share this year. This delisting offer therefore has no value for current shareholders who rejected Grifols' €30 offer. Remaining shareholders would lose value by accepting the delisting offer, which we believe is below fair market value. Those who want to dispose of their Biotest shares at depressed prices can do so on the stock exchange. Despite the lack of benefit – and the clear potential for harm – to minority shareholders, your board has agreed to support the delisting offer. What's more, you have done so in the absence of any formal fair value assessment. We believe this could indicate a lack of independence and a dereliction of the duties that both the management board and the supervisory board owe to all shareholders. Supporting an unfairly priced delisting offer is akin to supporting a below market value squeeze-out for those shareholders who must not hold unlisted equity. In our view, this would be a breach of the Biotest boards' fiduciary duties, at least with respect to minority shareholders. We would ask the boards of Biotest to withdraw their support for the delisting unless the offer price is increased to an IDW-S1-supported valuation, which is in turn based on a reasonable business plan. Further, the Company should clearly outline their mid-term plan and earnings potential, including the ramp up of Trimodulin production, and increase their shareholder outreach to ensure every shareholder has the same information about the Company's prospects. Yours Sincerely, Abhishek Agrawal Senior Portfolio Manager Westbourne River Partners Media Contact [email protected] +44 20 3890 9193 WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-08-28

·biotest.com

Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG

PRESS RELEASE Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG Dreieich, Germany, August 28, 2024. Biotest AG announced today that Dr. Jörg Schüttrumpf will in future focus on his role as Chief Scientific Innovation Officer of the entire Grifols Group. He will therefore resign from his position as Chief Scientific Officer and member of the Management Board of Biotest AG effective August 31, 2024. Biotest AG would like to take this opportunity to sincerely thank Dr. Schüttrumpf. Under his leadership, the company has achieved important milestones. The new Biotest products Fibrinogen and Trimodulin were developed, and Yimmugo® was the first product to be approved in Europe and the USA. All three products are part of the Biotest Next Level expansion program and are an important part of the Grifols Group pipeline through the technology transfer and licensing agreement. We look forward to the continued collaboration in his role within the Grifols Group. The areas of Biotest AG for which Dr. Schüttrumpf was previously responsible will in future be represented on the Management Board of Biotest AG by Mr. Janssen (CEO). About Biotest Biotest (www.biotest.com) is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com). IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406 Mail: ir@biotest.com PR contact Dirk Neumüller Phone: +49-6103-801-269 Mail: pr@biotest.com Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

高管变更上市批准引进/卖出

100 项与 Trimodulin (Biotest) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
管状汗腺腺瘤	临床3期	美国	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	阿根廷	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	澳大利亚	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	奥地利	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	比利时	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	巴西	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	捷克	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	法国	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	德国	Biotest GmbH & Co. KGaA	2023-09-09
管状汗腺腺瘤	临床3期	匈牙利	Biotest GmbH & Co. KGaA	2023-09-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04576728 (ESsCOVID, Pubmed \| Eur J Med Res) 人工标引	临床2期	新型冠状病毒感染	166	Trimodulin	顧選鑰簾廠鹽餘構餘夢(遞網襯餘獵鹽顧糧蓋網) = 壓壓餘壓糧醖觸網蓋鹹淵夢構窪觸網衊遞構廠 (鹹壓構餘艱餘鹽膚淵衊 )	不佳	2024-08-13
				Placebo	顧選鑰簾廠鹽餘構餘夢(遞網襯餘獵鹽顧糧蓋網) = 憲蓋糧醖膚觸糧窪獵繭淵夢構窪觸網衊遞構廠 (鹹壓構餘艱餘鹽膚淵衊 )
NCT01420744 (CIGMA, Pubmed \| Intensive Care Med)	临床2期	社区获得性肺炎追加	160	Trimodulin	願壓選繭夢繭鹽蓋鑰遞(廠鏇膚艱觸醖製構構艱) = 範壓築襯齋築壓積艱醖願廠齋築簾窪積衊窪淵 (窪遞憲衊選淵願遞壓積 )	-	2018-04-01
				Placebo	願壓選繭夢繭鹽蓋鑰遞(廠鏇膚艱觸醖製構構艱) = 構範構築襯構鑰蓋憲顧願廠齋築簾窪積衊窪淵 (窪遞憲衊選淵願遞壓積 )